Beta-Endorphin

Overview

Beta-endorphin (beta-EP) is a 31-amino-acid neuropeptide belonging to the endorphin class of endogenous opioids. First isolated from camel pituitary extracts in 1976 by Choh Hao Li, beta-endorphin represents one of the most potent naturally occurring analgesics. Its amino acid sequence, Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu, terminates the beta-lipotropin precursor at the C-terminus.

Biosynthetic Pathway

Beta-endorphin is derived from proopiomelanocortin (POMC), a 28.5 kDa precursor glycoprotein synthesized primarily in the anterior pituitary corticotrophs and hypothalamic arcuate nucleus. POMC undergoes tissue-specific proteolytic processing by prohormone convertase 1/3 (PC1/3) and carboxypeptidase E. In the anterior pituitary, adrenocorticotropic hormone (ACTH) and beta-lipotropin are the major products, with beta-endorphin cleaved from the C-terminus of beta-lipotropin. Additional cleavage by alpha-amidating enzyme generates the more potent des-acetyl forms.

Receptor Pharmacology

Beta-endorphin binds with high affinity (Kd approximately 1 nM) to mu-opioid receptors (MOR), though it also activates delta-opioid receptors (DOR) with somewhat lower affinity. MOR coupling to Gi/Go proteins inhibits adenylyl cyclase, opens inwardly rectifying potassium channels, and closes voltage-gated calcium channels. The resulting hyperpolarization suppresses neurotransmitter release in pain pathways.

Analgesic Properties

Beta-endorphin produces potent analgesia when administered intracerebroventricularly or intrathecally. The analgesic response is stereospecific and reversed by naloxone, confirming opioid receptor involvement. Beta-endorphin is particularly effective against acute nociceptive pain, with efficacy comparable to exogenous opioids like morphine. Unlike enkephalins, beta-endorphin resists enzymatic degradation by enkephalinases, resulting in prolonged duration of action.

Stress and Neuroimmune Modulation

Plasma beta-endorphin levels increase markedly during physiological stress, including exercise, pain, and immune challenges. This stress-induced release parallels ACTH secretion, reflecting their common POMC origin. Beta-endorphin modulates immune function by suppressing natural killer cell activity and lymphocyte proliferation through opioid receptor-dependent and -independent mechanisms.

Clinical Relevance

Altered beta-endorphin signaling has been implicated in depression, addiction, and chronic pain conditions. The “runner’s high” phenomenon has been attributed to exercise-induced beta-endorphin release. Beta-endorphin gene therapy is under investigation for treatment-refractory pain conditions.

References

1. Li, C.H. (1981). Beta-endorphin: a review. International Journal of Peptide and Protein Research, 17(3), 281-294.
2. Zadina, J.E., et al. (2003). Endomorphins and mu opioid receptors. Brain Research Reviews, 43(2), 145-166.
3. Molinoff, P.B., & Bhatt, D.L. (2006). Opioid peptides: biology and pharmacology. Cold Spring Harbor Perspectives in Medicine, 6(11), a025065.